In a recent randomized controlled trial published in The Journal of Clinical Endocrinology and Metabolism, researchers investigated the effects of retatrutide on lipid and metabolite profiles in participants living with obesity, both with and without type 2 diabetes (T2D). This phase II study aimed to assess the plasma metabolome and lipidome changes associated with retatrutide treatment.
The study involved two separate trials: one focusing on participants with obesity and the other on those with T2D. Participants were treated for durations of 36 and 48 weeks, respectively, with a total of 495 individuals enrolled across both trials. The treatment groups received varying doses of retatrutide or a placebo, while the T2D group also included a comparison to dulaglutide.
Results indicated that higher doses of retatrutide were associated with significant changes in a cluster of metabolites, including 3-hydroxybutyrate, acetylcarnitine, free carnitine, and long-chain acylcarnitines. Notably, mediation analyses suggested that these metabolic changes accounted for 23.2% of the weight reduction response in participants without T2D, while this mediation effect was reduced to 12.7% in those with T2D.
Additionally, retatrutide treatment led to alterations in metabolites linked to insulin resistance, such as branched-chain amino acids and their catabolic products, including 2-aminoadipic acid, 2-hydroxybutyrate, urate, and triglycerides enriched in short-chain and saturated acyl side chains. These findings were consistent across both study populations and were sustained throughout the study endpoints.
The conclusion drawn from this research is that retatrutide is associated with beneficial changes in metabolic health, particularly in relation to fatty acid oxidation and insulin resistance, which may contribute to reduced cardiovascular risk.
What this study does not show
This study does not establish a direct causal relationship between retatrutide treatment and improved health outcomes, as it primarily reports associations observed in the metabolic profiles.
Evidence scorecard
- Analytic validity: Established
- Clinical validity: Established
- Clinical utility: Partial
The evidence is based on a human randomized controlled trial.